Semax Peptide: The Russian-Developed Nootropic Backed by Clinical Use — Complete 2026 Guide

Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, with subsequent clinical development at Moscow State University. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro — a heptapeptide analogue of the 4–10 fragment of adrenocorticotropic hormone (ACTH), stabilized at the C-terminus with the Pro-Gly-Pro tripeptide to resist peptidase degradation.^[2]

The Pro-Gly-Pro extension is the key engineering decision. Without it, the ACTH(4-10) core has a plasma half-life measured in minutes. The extended version resists degradation long enough to reach CNS receptors — particularly via the intranasal route, where olfactory neuroepithelium provides a direct pathway bypassing the blood-brain barrier.^[3]

Semax is currently available in Russia and CIS countries as a licensed 0.1% or 1% nasal solution under the brand name "Semax." It is classified for research use only in the US, EU, and most Western markets.

Semax acts through multiple neurological pathways simultaneously, which is characteristic of peptides with broad clinical phenotypes. The three best-documented mechanisms are:

1. BDNF Upregulation

Brain-derived neurotrophic factor (BDNF) is the primary growth factor supporting neuronal survival, synaptic plasticity, and long-term potentiation — the cellular mechanism underlying learning and memory formation. Semax has been shown in multiple animal studies to significantly upregulate BDNF mRNA expression in the hippocampus and frontal cortex, with effects persisting for hours to days after single administration.^[4]

BDNF deficiency is implicated in depression, PTSD, Alzheimer's disease, and cognitive aging. Semax's ability to acutely increase BDNF expression is one of the key reasons it attracts interest in cognitive enhancement and neuroprotection research.

2. NGF and VEGF Enhancement

Beyond BDNF, Semax also upregulates nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in brain tissue. NGF supports cholinergic neuron maintenance, which is directly relevant to memory and attention. VEGF promotes cerebral angiogenesis — particularly significant in the context of stroke recovery, where restoring blood supply to ischemic penumbra tissue determines long-term functional outcome.^[5]

3. Dopaminergic and Serotonergic Modulation

Semax modulates dopamine turnover in the striatum and frontal cortex, with documented effects on dopamine release and reuptake kinetics. It also influences serotonergic signaling, which likely underlies the anxiolytic and mood-stabilizing effects reported by users — distinct from stimulant-like effects common to dopaminergic nootropics.^[6]

The clinical literature on Semax is predominantly published in Russian-language journals — a significant limitation for Western researchers who cannot readily access or evaluate these studies. The available translated and reviewed evidence includes:

• Stroke recovery (acute ischemic stroke): Multiple Russian clinical studies report that intranasal Semax (12–18 mcg/kg/day, equivalent to ~900 mcg–1.3 mg for a 75 kg adult) administered in the acute post-stroke period improved neurological outcomes, reduced lesion size on imaging, and accelerated functional recovery vs. standard of care alone.^[7]
• TIA and vascular cognitive impairment: Open-label clinical data suggests cognitive performance improvements in patients with transient ischemic attacks and cerebrovascular insufficiency, with standardized cognitive testing showing meaningful effects on attention, memory, and processing speed.^[8]
• ADHD (pediatric, Russian data): Limited open-label data shows Semax improves attention and reduces hyperactivity symptoms in children, though study quality and Western replication are absent.^[9]

Important caveats: most Russian studies are open-label, lack proper placebo controls, use non-standardized assessment tools, and were conducted at institutions with potential conflicts of interest. They should be treated as hypothesis-generating pilot data, not definitive proof of efficacy by Western regulatory standards.

Semax is available in nasal spray (0.1% = 1 mg/mL; 1% = 10 mg/mL) and as lyophilized powder for reconstitution. The intranasal route is preferred for CNS-targeted research due to the olfactory epithelium's direct access to brain tissue, bypassing systemic first-pass metabolism.^[10]

Intranasal (Primary Route)

• Research dose: 600 mcg–3 mg per day (0.1% solution: 2–3 drops per nostril, 2–3 times daily)
• Stroke/TIA research protocols: 600 mcg–1.2 mg twice daily for 10–14 days in the acute phase
• Cognitive/nootropic research: 300–600 mcg once or twice daily for 4–12 weeks
• Administration: Alternate nostrils; lie supine for 1–2 minutes after administration to improve nasal absorption

Subcutaneous Injection

• Research dose: 300–600 mcg SubQ once daily
• Half-life consideration: SubQ route bypasses olfactory direct-access pathway but provides more sustained plasma levels
• Reconstitution: 5 mg vial + 2.5 mL bacteriostatic water = 2,000 mcg/mL

Peptide Technologies offers Semax 5mg vials at $28.18 with ≥99.58% purity verified by third-party analysis — among the highest purity specifications for this peptide in the research market.^[11]

Semax and Selank are often discussed together as Russia's two flagship research nootropics. While they share some mechanistic overlap, their primary use cases diverge in clinically meaningful ways:

• Semax primarily targets BDNF/NGF upregulation, dopaminergic activation, and stroke-related neuroprotection. Users describe it as "activating" — better focus, faster processing, more drive. Associated with mild stimulant-like effects in some individuals.
• Selank is a synthetic analogue of tuftsin (a tetrapeptide from IgG immunoglobulin). Its primary profile is anxiolytic — it modulates GABA-A receptors and reduces anxiety without sedation. Users describe it as "calming but clear." Evidence base includes some Russian RCT data for generalized anxiety disorder.

The heuristic: if the research application centers on cognitive performance, learning, or neuroprotection — Semax. If it centers on anxiety, stress resilience, or anxious depression — Selank. Some researchers combine both at lower doses for the complementary effects.

Semax occupies a unique position: it is simultaneously one of the most evidence-supported cognitive peptides (by virtue of licensed clinical use in Russia) and one of the least understood by Western researchers (due to the Russian-language literature barrier). Its BDNF upregulation mechanism is scientifically sound, its clinical safety history is more extensive than most research peptides, and its cognitive effects in community use are remarkably consistent.

For researchers interested in neuroprotection, post-stroke cognitive recovery, or BDNF-mediated cognitive enhancement, Semax represents the strongest evidence-to-risk ratio in the cognitive peptide category. Source from vendors with verified purity COAs — Peptide Technologies' ≥99.58% specification is the benchmark in this category.